Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease (Q30651551)

20 August 2017

Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease (English)

1 reference

20 August 2017

0 references

1 reference

1 reference

Harald Hampel

2

0 references

Henrik Zetterberg

series ordinal

3

object named as

Henrik Zetterberg

1 reference

20 August 2017

1

Kaj Blennow

1 reference

PMCID

3857643

20 August 2017

language of work or name

English

0 references

publication date

25 June 2013

1 reference

20 August 2017

Neuropsychopharmacology

1 reference

20 August 2017

39

1 reference

20 August 2017

189-201

1 reference

20 August 2017

1

1 reference

Plasma tau levels in Alzheimer's disease

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Current therapeutic strategy in Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

TREM2 Variants in Alzheimer's Disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Plasma biomarkers for Alzheimer's disease: much needed but tough to find

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Immunotherapy for Alzheimer disease: the challenge of adverse effects.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Gantenerumab for the treatment of Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Brain imaging in the study of Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Tau-targeted treatment strategies in Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

PET imaging of brain amyloid in dementia: a review

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving be

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Believe it or not: how much can we rely on published data on potential drug targets?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Circulating neprilysin clears brain amyloid

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Thinking outside the box: Alzheimer-type neuropathology that does not map directly onto current consensus recommendations

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Natural human antibodies to amyloid beta peptide

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Lewy Body Pathology in Alzheimer's Disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Amyloid plaque core protein in Alzheimer disease and Down syndrome

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age.

20 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Biomarkers in Alzheimer's disease drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Biomarkers for Alzheimer's: the sequel of an original model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Correlation between scores for dementia and counts of 'senile plaques' in cerebral grey matter of elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2013.154

Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3857643

Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera

25 November 2018

1 reference

12 December 2020

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals

1 reference

12 December 2020

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

12 December 2020

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

12 December 2020

Identifiers

DOI

10.1038/NPP.2013.154

1 reference

PMCID

3857643

Dimensions Publication ID

20 August 2017

0 references

1 reference

20 August 2017

1 reference

PMCID

3857643